undamentalytics Newsletter
Sign in

Irhythm Holdings, Inc. (IRTC) stock

Add to watchlist

Add holding +

NASDAQ: IRTC Nasdaq Health Care Equipment Next results ~November 5, 2026

C+ Fundamentals grade

Irhythm Holdings, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$68

Valuation models combined (2)

Base case. Range ~$38–$83. Weighted average of 2 models (forward price-to-sales vs peers, revenue-to-maturity model).

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Irhythm Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 12 selling1 purchase and 65 sales by directors and officers, last 12 monthsInsider trades
  • Funds160 adding, 131 cuttingOf 63 active managers that changed their stake, 31 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Irhythm Holdings files

Where Irhythm stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $825m, up 25.6% on a year earlier, slower than the 27.4% growth a quarter earlier. That growth ranks 9 of 58 among the health care equipment companies we cover. Free-cash-flow margin held at 4.7%. Operating margin widened to -3.0% from -16.1%. The diluted share count is up 2.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $85.14 a share, against a share price of $128.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Irhythm Holdings, Inc.'s trailing-twelve-month revenue grew 25.6% year on year, with a free-cash-flow margin of 4.7%. Where it stands out: days sales outstanding of 37 days ranks 15 of 118 health care equipment companies we cover. Where it lags: long-term debt as % of assets of 59.5% ranks 80 of 87 health care equipment companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 1258% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 25.6% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 13.1 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 17.3% over 90 days.

Things to watch

  • Loss-making. Operating margin is -3.0%: costs exceed revenue.
  • Share dilution. Diluted shares rose 2.9% in a year.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 59.5% ranks 80 of 87 health care equipment companies we cover (median 24.2%).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.58 against an average estimate of $0.04: beat by 1258.0%
Revenue
$224m, up 20.1% on a year earlier
Share reaction
+2.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
revenue $880m to $890m (full year 2026); adjusted EBITDA margin 13% to 14% (full year 2026)
Next report
November 5, 2026; average EPS estimate $0.05

Irhythm Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.3%
  • 1 week+3.5%
  • 1 month+14.3%
  • This year-28.9%
  • 1 year-32.6%
  • 5 years+3.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$825M
Operating margin
-3.0%
Net margin
-1.7%
EPS (TTM, diluted)
$-0.43

Growth

Revenue growth
+25.6%
Change in growth rate
−1.8 pts
Share count change
+2.9%

Cash

Free cash flow (TTM)
$39M
FCF margin
4.7%
Stock pay % of revenue
10.1%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Leadership
  4. Insider trade
  5. Agreement
  6. Results
  7. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Irhythm Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Irhythm Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.92 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$23 ~$15–$30 Left out: out of range vs price (0.18x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$18–$32 Left out: out of range vs price (0.16x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$38 ~$42–$150 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$83 ~$67–$100 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$68 ~$38–$83 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Irhythm Holdings, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$30.00$56.05$69.48$68.09$237.21$117.69$93.67$107.04$90.17$177.44$126.17
Market value$159m$1.3bn$1.7bn$1.7bn$6.6bn$3.5bn$2.8bn$3.3bn$2.8bn$5.7bn$4.1bn
+ Net debt (− = net cash)−$5m$36m$15m$14m−$56m−$106m−$44m−$1m$227m$413m$404m
Enterprise value$153m$1.3bn$1.7bn$1.7bn$6.5bn$3.3bn$2.8bn$3.3bn$3.0bn$6.1bn$4.5bn
Multiples
Price / sales 2.5x12.8x11.3x8.0x24.8x10.7x6.8x6.6x4.8x7.6x5.0x
Price / earnings ———————————
Price / free cash flow —————————164.5x105.1x
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

34 /100

Weak moat

How hard Irhythm Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -7.3% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 70.7%, moving by 2.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -22.4%; its worst year was -35.2%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -17.9% of revenue.

  • Discipline 3 / 20

    The diluted share count rose 12.4% over five years; stock-based pay has been a median 11.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $222m and EPS of $0.05 (range −$0.08 to $0.14) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.55 +154% $892m +19%
Next $1.25 +125% $1.0bn +17%

Next year's EPS estimate has moved +17.3% in 90 days, across 7 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +349.6% on 90 days ago. In the last 30 days, 1 analyst raised Irhythm Holdings, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Irhythm Holdings, Inc., last 90 days
$0.00 $0.50 $1.00 $1.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.12 Current fiscal year, 60 days ago: $0.58 Current fiscal year, 30 days ago: $0.58 Current fiscal year, 7 days ago: $0.57 Current fiscal year, Now: $0.55 $0.55 Next fiscal year, 90 days ago: $1.06 Next fiscal year, 60 days ago: $1.20 Next fiscal year, 30 days ago: $1.20 Next fiscal year, 7 days ago: $1.28 Next fiscal year, Now: $1.25 $1.25

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.12$1.06
60 days ago $0.58$1.20
30 days ago $0.58$1.20
7 days ago $0.57$1.28
Now $0.55$1.25

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.04 $0.58 +1258.0%
Mar 2026 −$0.64 −$0.35 +45.3%
Dec 2025 $0.06 $0.29 +410.6%
Sept 2025 −$0.28 −$0.06 +78.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • revenue full year 2026 $880m to $890m Raised
    “For the full year 2026, iRhythm expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.” source
  • adjusted EBITDA margin full year 2026 13% to 14% Non-GAAP Raised
    “For the full year 2026, iRhythm expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

16 analysts, Oct 2026
Buy16100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202631316
  2. Sep 202621315
  3. Aug 202621315
  4. Jul 202621315

Counts of recommendations published by analysts covering Irhythm Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.5%
of tradable shares
Days to cover
6.26
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.2%
of shares
Employees
2,400
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −32.6%

$187.30 on October 31, 2025 to $126.17

ThenNowEffect
Revenue (last 12 months) $657m $825m +25.6%
P/S multiple 9.0x 5.0x −44.8%
Share count 32m 32m −2.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +51.5%

$83.28 on November 3, 2023 to $126.17

ThenNowEffect
Revenue (last 12 months) $452m $825m +82.6%
P/S multiple 5.6x 5.0x −11.0%
Share count 30m 32m −6.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IRTC−50%−20%+14%−16%+97%−29%
Industry peers (median)−7%−37%−9%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IRTC33%50%58%42%75%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IRTC−84%−47%−48%−54%−19%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 20, 2016: 84% from January 20, 2021 to August 19, 2021. Getting back needed a 541% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$101.79 – $189.25
From 52-week high
−33.3%
vs 50-day average
+9.7%
vs 200-day average
+3.3%
Volatility (1 year)
44%
Beta vs S&P 500
0.58

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.9%
After a week
5 up, 7 down
typical move ±9.2%
After a month
4 up, 8 down
typical move ±11.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +2.7% +0.5% −1.1% −1.1%
April 30, 2026 0.0% +1.3% +3.4% −9.6%
February 19, 2026 −1.9% +0.5% −8.9% −24.4%
October 30, 2025 +1.1% −0.8% −4.3% −1.4%
July 31, 2025 +17.8% −2.0% +14.9% +21.3%
February 20, 2025 +5.7% −2.1% −5.7% −7.6%
October 30, 2024 −5.9% −2.3% +16.2% +12.9%
August 1, 2024 −14.3% −3.3% −17.8% −17.8%
May 2, 2024 −8.1% +2.2% −10.6% −24.8%
February 22, 2024 −6.1% +2.1% +6.0% −3.2%
November 2, 2023 +5.5% +2.8% −7.9% +14.0%
August 3, 2023 +13.9% −0.7% +13.0% +1.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Irhythm Holdings, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Irhythm Holdings, Inc.
$400M $500M $600M $700M $800M $900M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $472.8M Revenue (TTM), FY23 Q4: $492.7M Revenue (TTM), FY24 Q1: $513.2M Revenue (TTM), FY24 Q2: $537.1M Revenue (TTM), FY24 Q3: $560M Revenue (TTM), FY24 Q4: $591.8M Revenue (TTM), FY25 Q1: $618.6M Revenue (TTM), FY25 Q2: $657.2M Revenue (TTM), FY25 Q3: $702.6M Revenue (TTM), FY25 Q4: $747.1M Revenue (TTM), FY26 Q1: $787.9M Revenue (TTM), FY26 Q2: $825.3M $825.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $472.8M
FY23 Q4 $492.7M
FY24 Q1 $513.2M
FY24 Q2 $537.1M
FY24 Q3 $560M
FY24 Q4 $591.8M
FY25 Q1 $618.6M
FY25 Q2 $657.2M
FY25 Q3 $702.6M
FY25 Q4 $747.1M
FY26 Q1 $787.9M
FY26 Q2 $825.3M
Revenue growth, TTM YoY Irhythm Holdings, Inc.
15% 20% 25% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 24.4% Revenue growth, TTM YoY, FY23 Q4: 19.9% Revenue growth, TTM YoY, FY24 Q1: 19.3% Revenue growth, TTM YoY, FY24 Q2: 18.8% Revenue growth, TTM YoY, FY24 Q3: 18.5% Revenue growth, TTM YoY, FY24 Q4: 20.1% Revenue growth, TTM YoY, FY25 Q1: 20.5% Revenue growth, TTM YoY, FY25 Q2: 22.4% Revenue growth, TTM YoY, FY25 Q3: 25.5% Revenue growth, TTM YoY, FY25 Q4: 26.2% Revenue growth, TTM YoY, FY26 Q1: 27.4% Revenue growth, TTM YoY, FY26 Q2: 25.6% 25.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 24.4%
FY23 Q4 19.9%
FY24 Q1 19.3%
FY24 Q2 18.8%
FY24 Q3 18.5%
FY24 Q4 20.1%
FY25 Q1 20.5%
FY25 Q2 22.4%
FY25 Q3 25.5%
FY25 Q4 26.2%
FY26 Q1 27.4%
FY26 Q2 25.6%
Operating margin (TTM) Irhythm Holdings, Inc.
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -22.6% Operating margin (TTM), FY23 Q4: -25.4% Operating margin (TTM), FY24 Q1: -24.1% Operating margin (TTM), FY24 Q2: -23.8% Operating margin (TTM), FY24 Q3: -26.9% Operating margin (TTM), FY24 Q4: -19.5% Operating margin (TTM), FY25 Q1: -17.8% Operating margin (TTM), FY25 Q2: -16.1% Operating margin (TTM), FY25 Q3: -9.1% Operating margin (TTM), FY25 Q4: -7.7% Operating margin (TTM), FY26 Q1: -5.2% Operating margin (TTM), FY26 Q2: -3.0% -3.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -22.6%
FY23 Q4 -25.4%
FY24 Q1 -24.1%
FY24 Q2 -23.8%
FY24 Q3 -26.9%
FY24 Q4 -19.5%
FY25 Q1 -17.8%
FY25 Q2 -16.1%
FY25 Q3 -9.1%
FY25 Q4 -7.7%
FY26 Q1 -5.2%
FY26 Q2 -3.0%
FCF margin (TTM) Irhythm Holdings, Inc.
-30% -20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -11.8% FCF margin (TTM), FY23 Q4: -18.4% FCF margin (TTM), FY24 Q1: -22.0% FCF margin (TTM), FY24 Q2: -17.8% FCF margin (TTM), FY24 Q3: -12.9% FCF margin (TTM), FY24 Q4: -5.2% FCF margin (TTM), FY25 Q1: 2.3% FCF margin (TTM), FY25 Q2: 4.2% FCF margin (TTM), FY25 Q3: 4.6% FCF margin (TTM), FY25 Q4: 4.6% FCF margin (TTM), FY26 Q1: 2.4% FCF margin (TTM), FY26 Q2: 4.7% 4.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -11.8%
FY23 Q4 -18.4%
FY24 Q1 -22.0%
FY24 Q2 -17.8%
FY24 Q3 -12.9%
FY24 Q4 -5.2%
FY25 Q1 2.3%
FY25 Q2 4.2%
FY25 Q3 4.6%
FY25 Q4 4.6%
FY26 Q1 2.4%
FY26 Q2 4.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 22 36 64 99 147 215 265 323 411 493 592 747 825
Gross profit 11 21 43 71 108 162 195 214 282 332 408 527 590
EBITDA −15 −21 −15 −26 −43 −51 −37 −90 −100 −109 −95 −37 −4
Operating income −15 −22 −16 −28 −46 −55 −44 −100 −114 −125 −116 −57 −25
Net income −16 −23 −21 −30 −50 −55 −44 −101 −116 −123 −113 −45 −14
Diluted EPS −$3.01 −$4.14 −$3.95 −$1.31 −$2.11 −$2.16 −$1.58 −$3.46 −$3.88 −$4.04 −$3.63 −$1.39 −$0.43
Growth (year on year)
Revenue — +66.2% +77.3% +54.7% +48.6% +45.7% +23.6% +21.7% +27.3% +19.9% +20.1% +26.2% +25.6%
Margins
Gross margin 51.3% 59.3% 67.4% 71.5% 73.7% 75.5% 73.5% 66.2% 68.5% 67.3% 68.9% 70.6% 71.5%
EBITDA margin −66.8% −58.5% −23.4% −26.2% −29.5% −23.9% −13.9% −27.9% −24.4% −22.1% −16.0% −4.9% −0.5%
Operating margin −67.9% −59.9% −24.3% −27.8% −31.0% −25.5% −16.5% −31.0% −27.7% −25.4% −19.5% −7.7% −3.0%
Net margin −72.8% −63.1% −32.6% −30.0% −34.2% −25.4% −16.5% −31.4% −28.3% −25.0% −19.1% −6.0% −1.7%
Free-cash-flow margin −74.3% −54.8% −30.3% −18.6% −23.3% −19.7% −10.3% −20.4% −12.9% −18.4% −5.2% 4.6% 4.7%
Cash flow
Cash from operations −16 −18 −17 −15 −29 −22 −14 −38 −23 −50 3 81 86
Capital spending 1 2 3 4 5 20 14 28 30 40 34 46 47
Free cash flow −16 −20 −19 −18 −34 −42 −27 −66 −53 −91 −31 35 39
Stock-based pay 1 1 2 10 16 26 42 55 58 77 76 88 84
Free cash flow after stock pay −17 −21 −21 −28 −51 −69 −69 −120 −111 −168 −107 −54 −45
Balance sheet
Cash 9 25 52 9 20 20 89 128 79 36 420 236 247
Total debt 0 31 46 45 35 35 33 21 35 35 646 650 651
Net debt (negative = net cash) −9 5 −5 36 15 14 −56 −106 −44 −1 227 413 404
Diluted shares 5m 6m 5m 23m 24m 25m 28m 29m 30m 31m 31m 32m 32m
Returned to shareholders
Buybacks — — — — — — — — 0 0 25 0 —
Total returned — — — — — — — — 0 0 25 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $1.1bn
Short-term assets $756mLonger-term assets $337m
What it owes, and who funded it · $1.1bn
Short-term liabilities $196mLonger-term liabilities $711mShareholders' equity $186m
  • Short-term assets cover short-term liabilities $756m of assets due within a year against $196m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $756m short-term assets against $711m of longer-dated liabilities.
  • More cash than debt $247m of cash against $651m of debt.
  • Debt below 40% of shareholders' equity Debt is 350% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 3% to 350% over five years.
  • A year's operating cash flow covers at least 20% of debt $86m of operating cash flow against $651m of debt.
  • Operating profit covers interest at least five times over Operating income of −$25m against $13m of interest.

From Irhythm Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$25M
Diluted share count
+2.9%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
10.1%
of revenue
Sales & admin spending
62.2%
of revenue
Days sales outstanding
37 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated IRTC OFIX ATEC MYGN VREX INSP Median
Revenue, last 12 months $825m $833m $840m $807m $865m $881m $99m
Revenue growth, last 12 months 25.6% 3.0% 15.3% −3.2% 5.3% −0.2% 9.2%
Revenue growth, 3-year average 22.2% 11.7% 23.1% 4.9% −1.2% 15.6% 13.5%
Revenue growth, latest quarter 20.1% 3.8% 12.6% −10.5% 3.7% −7.9% 10.2%
Gross margin 71.5% 71.3% 71.3% 68.8% 34.3% 86.2% 61.2%
Operating margin −3.0% −4.7% −3.6% −12.2% 8.3% 1.8% −8.5%
Operating margin, 3-year average −14.3% −9.7% −14.8% −27.2% 3.1% 2.6% −17.9%
Net margin −1.7% −7.4% −10.3% −14.0% 2.6% 11.4% −12.0%
Cash from operations / revenue 10.4% 2.0% 7.3% 1.0% 1.3% 15.3% −1.9%
Free-cash-flow margin 4.7% −3.3% −1.2% −4.2% −2.3% 11.1% −3.9%
Free-cash-flow margin, 3-year average −3.0% −4.2% −12.1% −10.5% 2.4% 9.1% −7.0%
Stock pay / revenue 10.1% 3.4% 9.0% 3.6% 1.7% 13.3% 6.1%
Change in share count 2.9% 3.6% 4.6% 2.5% −8.8% −3.9% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 25.6% 9.1% 30 of 129
Change in growth rate Growth -1.8pp -0.6pp 84 of 129
Gross margin Profitability 71.5% 61.9% 34 of 123
Operating margin Profitability -3.0% -8.3% 52 of 132
Net margin Profitability -1.7% -12.0% 47 of 133
Free-cash-flow margin Cash generation 4.7% -3.4% 42 of 128
Stock pay as % of revenue Cash generation 10.1% 6.1% 77 of 123
Long-term debt as % of assets Balance sheet 59.5% 24.2% 80 of 87
Change in share count Balance sheet 2.9% 3.3% 54 of 115
Days sales outstanding Balance sheet 37 days 57 days 15 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Commercial Payors $392M 52.5% ▲ 25.9%
Centers For Medicare and Medicaid $179M 24.0% ▲ 26.0%
Healthcare Institutions $126M 16.8% ▲ 32.1%
Non Contracted Third Party Payors $49.9M 6.7% ▲ 16.9%

From Irhythm Holdings, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$4.2B
Institutions reporting
304
Shares held vs prior quarter
▲ 0.3%
Positions opened / closed
40 / 40

Top buyers and sellers, Q2 2026: 160 institutions bought and 131 sold ; the biggest buyer was RTW Investments, LP (+514K shares) and the biggest seller Holocene Advisors, LP (−465K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $355M 3.0M 8.4% ▲ 8.9%
RTW Investments, LP $260M 2.2M 6.1% ▲ 30.8%
Vanguard Portfolio Management LLC $228M 1.9M 5.4% ▲ 6.5%
Artisan Partners Limited Partnership $197M 1.7M 4.7% ▲ 14.4%
Vanguard Capital Management LLC $174M 1.5M 4.1% ▲ 1.2%
Millennium Management LLC $167M 1.4M 3.9% ▼ 12.5%
FMR LLC $142M 1.2M 3.3% ▼ 12.5%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $112M 945K 2.6% ▼ 9.8%
Geode Capital Management, LLC $105M 882K 2.5% ▲ 7.9%
Eventide Asset Management, LLC $105M 880K 2.5% ▲ 15.7%
BNP Paribas Asset Management Holding S.A. $103M 867K 2.4% ▲ 13.7%
State Street Corp $102M 857K 2.4% ▲ 8.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Irhythm Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $56,892 1 trade by 1 insider, last 12 months Insider sales History → $28M 65 trades by 12 insiders · 10% under pre-set plans
Net ▼ $27.9M net selling
Insider Date Trade Shares Price Value
Wilson Daniel G. Chief Financial Officer September 2, 2026 Sell 773 $121.83 $94,175
Turakhia Minang CHIEF MED/SCI OFCR EVP ADVTECH August 10, 2026 Sell 7,093 $124.65 $884,142
Shrishrimal Sumi EVP, Chief Risk Officer August 10, 2026 Sell 5,372 $124.65 $669,620
Patterson Chad CHIEF COMM & PRODUCT OFFICER August 10, 2026 Sell 7,093 $124.65 $884,142
Murphy Patrick Michael CBO and CLO August 10, 2026 Sell 7,093 $124.65 $884,142
Blackford Quentin S. President and CEO August 10, 2026 Sell 26,859 $124.65 $3.3M
Patterson Chad CHIEF COMM & PRODUCT OFFICER August 3, 2026 Sell 2,712 $122.12 $331,189
Rodda Julianne EVP, CHIEF PEOPLE OFFICER August 3, 2026 Sell 2,112 $122.12 $257,917
Smith Mervin EVP Strategic Business Ops August 3, 2026 Sell 617 $122.12 $75,348
Freeman Sean Clinton EVP, Strategy & Corp Devt July 2, 2026 Sell 918 $124.71 $114,484
Turakhia Minang CHIEF MED/SCI OFCR EVP ADVTECH July 2, 2026 Sell 1,423 $124.71 $177,462
Rosenbaum Marc Wade Chief Accounting Officer June 2, 2026 Sell 729 $108.19 $78,871

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Irhythm Holdings, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Donna Shalala(FL):Sale (full), $1,001 - $15,000, traded June 24, 2019, filed April 27, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • April 30, 2026
  • February 19, 2026
  • October 30, 2025
  • July 31, 2025
  • February 20, 2025

Recent SEC filings

Data status

When each part of this page on Irhythm Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Irhythm Holdings, Inc. in brief

What does Irhythm Holdings, Inc. do?
Irhythm Holdings, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Irhythm Holdings, Inc.'s stock ticker?
Irhythm Holdings, Inc. trades under the ticker IRTC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Irhythm Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Irhythm Holdings, Inc. reported revenue of $825M, 25.6% higher than a year earlier, according to its SEC filings.
What is Irhythm Holdings, Inc.'s free cash flow?
Irhythm Holdings, Inc.'s free-cash-flow margin is 4.7% of revenue over the trailing twelve months, ranking 42 of the 128 health care equipment companies we cover.
Who are Irhythm Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., RTW Investments, LP and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Irhythm Holdings, Inc. buying back stock, and does it pay a dividend?
Irhythm Holdings, Inc. spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 2.9% over the year.
What is Irhythm Holdings, Inc.'s market cap?
On November 2, 2026, Irhythm Holdings, Inc.'s market capitalisation was about $4.1B and net debt of $404M. Market figures come from third-party market data and may be delayed.
How much debt does Irhythm Holdings, Inc. have?
Irhythm Holdings, Inc.'s debt-to-equity ratio is 350.1%, from its latest balance sheet (3.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Irhythm Holdings, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Irhythm Holdings, Inc. are Orthofix Medical Inc., Alphatec Holdings, Inc., Myriad Genetics Inc, Varex Imaging Corp and Inspire Medical Systems, Inc. The side-by-side comparison below sets their revenue, margins and growth against Irhythm Holdings, Inc.'s.
Are insiders buying or selling Irhythm Holdings, Inc. stock?
Over the last 12 months, Irhythm Holdings, Inc.'s directors and officers reported 1 open-market purchases and 65 sales on Form 4. The insider trading page charts every trade.
When is Irhythm Holdings, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Irhythm Holdings, Inc. announces its own schedule.